IP Library Granted Patent US 8,980,282
Granted Patent B2
US 8,980,282 · App. 12/670,551 · Granted Mar 17, 2015

Viruses

Inventor: Joe Conner (Glasgow, GB)
Assignee: Virttu Biologics Limited
A61K47/48776A61K47/48561A61K47/48623A61K47/48638
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,282
App. No.
12/670,551
Granted
Mar 17, 2015
Kind
B2
Abstract

Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.

Claims (12)

1. A herpes simplex virus (HSV) comprising an N-terminally truncated glycoprotein D linked to a targeting agent, wherein the N-terminally truncated glycoprotein D has a truncation of at least up to position 260 of the full-length HSV-1 glycoprotein D, wherein the truncation is no greater than or equal to position 274 of the full-length HSV-1 glycoprotein D.

2. A HSV according to claim 1 , wherein the N-terminally truncated glycoprotein D has an extracellular domain comprising at least 42 amino acids.

3. A HSV according to claim 1 , wherein the N-terminally truncated glycoprotein D has an extracellular domain comprising a portion of amino acids corresponding to amino acids 274-315 of the full-length HSV-1 glycoprotein D.

4. A HSV according to claim 1 , wherein targeting agent and the N-terminally truncated glycoprotein D are a fusion protein.

5. A HSV according to claim 1 , wherein the targeting agent is an antibody binding domain.

6. A HSV according to claim 1 , wherein the targeting agent and N-terminally truncated HSV-1 glycoprotein D are a fusion protein, and wherein the targeting agent is an antibody binding domain.

7. A HSV according to claim 1 , wherein the N-terminally truncated glycoprotein D is an N-terminal truncate of a glycoprotein D having the amino acid sequence of SEQ ID NO: 1.

8. A HSV according to claim 1 , wherein the targeting agent is specific for a target selected from the group consisting of GD3, CD38, CD55, CD20, EGRF, HER2/neu, CEA, squamous cell carcinoma antigens 1 and 2, ovarian carcinoma antigen CA125, Mucin 1, prostate-specific membrane antigen, melanoma-associated tumour antigen p97, 5T4 oncofoetal trophoblast glycoprotein, CA19-9, CA72-4 and CA195.

9. A HSV according to claim 1 , wherein the HSV is a mutant of HSV-1.

10. A HSV according to claim 1 , wherein the HSV is non-neurovirulent.

11. A HSV according to claim 1 , wherein the HSV does not comprise an ICP34.5 gene that encodes a functional ICP34.5 gene product.

12. A HSV according to claim 1 , wherein the HSV is a mutant of HSV1716.

Assignments (2)
CHANGE OF NAME Recorded Feb 9, 2015
From: CRUSADE LABORATORIES LIMITED
To: VIRTTU BIOLOGICS LIMITED
Reel/Frame 034920/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2010
From: CONNER, JOE
To: CRUSADE LABORATORIES LIMITED
Reel/Frame 024655/0330 →
Priority Claims (1)
GB 0714578.2 · Jul 26, 2007 · national
Continuity (1)
Related Publication 20100272691A1 · Oct 28, 2010